The notices it replaced
- Reissues: PA-14-071 PHS 2014-02 Omnibus Solicitation of the NIH, CDC, FDA and ACF for Small Business Innovation Research Grant Applications (Parent SBIR [R43/R44])
- 2 steps back: PA-13-234 Reissue PHS 2013-02 Omnibus Solicitation of the NIH, CDC, FDA and ACF for Small Business Innovation Research Grant Applications (Parent SBIR [R43/R44])
- 3 steps back: PA-13-088 PHS 2013-02 Omnibus Solicitation of the NIH, CDC, FDA and ACF for Small Business Innovation Research Grant Applications (Parent SBIR [R43/R44])
- 4 steps back: PA-12-088 PHS 2012-02 Omnibus Solicitation of the NIH, CDC, FDA and ACF for Small Business Innovation Research Grant Applications (Parent SBIR [R43/R44])
- 5 steps back: PA-11-096 PHS 2011-02 Omnibus Solicitation of the NIH, CDC, FDA and ACF for Small Business Innovation Research Grant Applications (Parent SBIR [R43/R44])
- 6 steps back: PA-10-050 PHS 2010-02 Omnibus Solicitation of the NIH, CDC, FDA and ACF for Small Business Innovation Research Grant Applications (Parent SBIR [R43/R44])
- 7 steps back: PA-09-080 PHS 2009-02 Omnibus Solicitation of the NIH, CDC, FDA and ACF for Small Business Innovation Research Grant Applications (Parent SBIR [R43/R44])
Replaced by PA-16-302.
Who won it before
2,074 competing awards (new and renewals) from FY2014 to FY2025 under this notice and the notices it replaced: $722,483,375 in first-year total cost, median $224,999.
Most frequent study sections
- Special Emphasis Panel[ZRG1 ETTN-G (12)]132
- Special Emphasis Panel[ZRG1 ETTN-M (11)]106
- Special Emphasis Panel[ZRG1 SBIB-T (10)]98
- Special Emphasis Panel[ZRG1 RPHB-C (10)]87
- Special Emphasis Panel[ZRG1 IDM-V (12)]68
Most frequent institutions
- PANORAMA RESEARCH, INC.19
- PROGENRA, INC.15
- AFFINERGY, LLC14
- PHYSICAL SCIENCES, INC12
- 3-C INSTITUTE FOR SOCIAL DEVELOPMENT10
| FY | Project | PIs | Institution | First-year cost | Study section |
|---|---|---|---|---|---|
| 2017 | Enzyme replacement therapy for GM1 gangliosidosis lysosomal rare disease2R44NS084565-02 | ACOSTA, WALTERCRAMER, CAROLE L.D'AZZO, ALESSANDRARADIN, DAVID | BIOSTRATEGIES, LC, AR | $1,366,586 | ZRG1 |
| 2017 | TempO-Seq: A Multiplexed Gene Expression Profiling Platform2R44HG007339-03 | YEAKLEY, JOANNE MULLIGAN | BIOSPYDER TECHNOLOGIES, INC., CA | $1,258,482 | ZRG1 |
| 2017 | Safety and Efficacy Testing of FX101 in an SIV/NHP Model2R44MH096663-03A1 | BOLTON, DIANE L.KAY, HEIDI ARAPPAPORT, JAY | JERICHO SCIENCES, LLC, VA | $1,154,643 | ZRG1 |
| 2017 | Production Technology for Recombinant Intravenous Immunoglobulin2R44AI115892-02A1 | JOHNSON, DAVID SCOTT | GIGAGEN, INC., CA | $1,000,000 | ZRG1 |
| 2017 | Advanced PML antiviral2R44AI103982-04 | WERNER, MILTON H. | INHIBIKASE THERAPEUTICS, GA | $1,000,000 | ZRG1 |
| 2017 | A Phase III Trial to Validate HP 129Xe MRI as a Functional Pulmonary Biomarker in Pediatric Lung Disease2R44HL123299-02A1 | EMAMI, KIARASH | POLAREAN, INC., NC | $999,713 | ZRG1 |
| 2017 | Selective Depletion of Insulin-Specific B cells to Prevent Type 1 Diabetes2R44DK107099-02 | ZION, TODD C | AKSTON BIOSCIENCES CORPORATION, MA | $998,123 | ZRG1 |
| 2017 | TempO-Seq for Preserved Tissues in Toxicity Testing Phase II2R44ES024107-02 | SELIGMANN, BRUCE E. | BIOSPYDER TECHNOLOGIES, INC., CA | $979,864 | ZRG1 |
| 2017 | Analytical Methods for Automated Quality Control of Cancer PET Imaging Tracer - [F-18]FDG2R44CA192499-02 | ELIZAROV, ARKADIJ | TRACE-ABILITY, INC., CA | $859,830 | ZRG1 |
| 2017 | Product Development for Bromodomain Networks2R44TR001268-02 | MA, HAICHING | REACTION BIOLOGY CORPORATION, PA | $848,800 | ZRG1 |
| 2017 | Automated Isolation of Single Cells Using High-Resolution and Subcellular Imaging2R44GM119888-02A1 | GEBHART, STEVEN CHARLES | CELL MICROSYSTEMS, INC., NC | $818,501 | ZRG1 |
| 2017 | High Energy Density, Long Life, Betavoltaic Power Cells for Pacemakers and other Implantable Devices2R44HL127706-02 | THOMAS, CHRIS | WIDETRONIX, INC., NY | $773,585 | ZRG1 |
| 2017 | HOME: Monitoring Balance and Gait with the Home Objective Mobility Exam2R44AG044863-03 | EL-GOHARY, MAHMOUDHORAK, FAY BAHLING | APDM, INC., OR | $767,705 | ZRG1 |
| 2017 | Ubiquitin pathway inhibitors for treatment of asthma2R44AI109980-02A1 | SURESH, KUMAR | PROGENRA, INC., PA | $757,044 | ZRG1 |
| 2017 | Large Scale Synthesis of the Next Generation Synthetic Saponin Adjuvant TiterQuil2R44AI114030-02 | LIVINGSTON, PHILIP O. | ADJUVANCE TECHNOLOGIES, INC., NY | $756,567 | ZRG1 |
| 2017 | PicoSep - A Microfluidic Platform for Single Molecule DNA and RNA Sizing2R44GM103356-03A1 | LIU, KELVINWANG, TZA-HUEI JEFF | CIRCULOMICS, INC., MD | $746,273 | ZRG1 |
| 2017 | Cell Line Panel Profiling for Discovery of Multiple Myeloma Therapeutics2R44CA183470-02 | KRUTZIK, PETER | PRIMITY, INC., CA | $745,194 | ZRG1 |
| 2017 | Development of an improved, low-cost polio vaccine (Ir-IPV)2R44AI120260-02 | TOBIN, GREGORY JOHN | BIOLOGICAL MIMETICS, INC., MD | $743,104 | ZRG1 |
| 2017 | Tools for Faster and Cheaper Delivery of Integrated Registries2R44MH099826-03A1 | ROZENBLIT, LEON | PROMETHEUS RESEARCH, LLC, CT | $742,523 | ZRG1 |
| 2017 | Competitive Equilibrium-based Displacement of Bisphosphonates as Novel Therapeutic Approach for BRONJ2R44DE025524-02 | EBETINO, FRANK H. | BIOVINC, LLC, CA | $740,777 | ZRG1 |
| 2017 | High-throughput Identification of Membrane Protein MAbs2R44GM113556-02A1 | DORANZ, BENJAMIN J | INTEGRAL MOLECULAR, PA | $686,432 | ZRG1 |
| 2017 | CRISPR Genome-Wide sgRNA Library Screening Platform2R44HG008578-02 | TEDESCO, DONATO | CELLECTA, INC., CA | $651,831 | ZRG1 |
| 2017 | A New Approach to Vision Therapy Based on Naturalistic 3-D Computer Gaming2R44EY021079-05 | ADAMS, RICHARD J. | BARRON ASSOCIATES, INC., VA | $627,545 | ZRG1 |
| 2017 | Development of high-throughput cardiotoxicity and hepatotoxicity assays with magnetic 3D bioprinting2R44ES024644-02A1 | TSENG, HUBERT | NANO3D BIOSCIENCES, INC., TX | $623,123 | ZRG1 |
| 2017 | Optimization of Supercritical Carbon Dioxide Based Virus Inactivation, Characterized by Protein Damage and Maintenance of Epitope Integrity in Vaccine Sterilization2R44AI120282-02 | FEY, JULIEN | NOVASTERILIS, INC., NY | $608,082 | ZRG1 |
| 2017 | Localized Delivery of Sirolimus to Hemodialysis Vascular Access Grafts1R44AG059279-01A1 | ROY-CHAUDHURY, PRABIRSHEBUSKI, RONALD J. | CYLERUS, INC., FL | $603,715 | ZRG1 |
| 2017 | Phase II: Feasibility assessment of a novel tool for mosquito vector control: Auto-Dissemination Augmented by Males (ADAM)2R44AI112048-02 | KELLY, PATRICK | MOSQUITOMATE, INC., KY | $597,201 | ZRG1 |
| 2017 | A device for monitoring heart failure patients2R44HL099053-02A1 | SANDLER, RICHARD HAROLD | BIOMEDICAL ACOUSTICS RESEARCH COMPANY, FL | $570,451 | ZRG1 |
| 2017 | Next Generation Western for high-throughput and high-content protein analysis2R44GM112289-03 | FURTAW, MICHAEL D | LI-COR BIOSCIENCES, INC., NE | $548,838 | ZRG1 |
| 2017 | On-line Measurement of the Capacity of Airborne Particulate Matter to Generate Reactive Oxygen Species2R44ES025468-02 | EIGUREN FERNANDEZ, ARANTZAZU | AEROSOL DYNAMICS, INC., CA | $518,991 | ZRG1 |
| 2017 | Endotoxin Neutralization as a Biomonitor for HIV Disease Progression2R44AI114445-02A1 | CHAMPION, KEITH | BIODTECH, INC., AL | $501,326 | ZRG1 |
| 2017 | Using Technology to Improve Clinical Counseling of Adolescent Risky Behaviors2R44DA037623-02A1 | SALERNO, JENNIFER | POSSIBILITIES FOR CHANGE, LLC, MI | $499,508 | ZRG1 |
| 2017 | Monitoring Pesticide Exposure and Accumulation: An Improved Rapid Identifier for all Pesticide Classes2R44ES024617-02 | SPENCER, KEVIN M | EIC LABORATORIES, INC., MA | $489,112 | ZRG1 |
| 2017 | Drug Delivery Method for Sudden Sensorineural Hearing Loss2R44DC013534-02A1 | WEINBERG, IRVING | WEINBERG MEDICAL PHYSICS, LLC, MD | $484,330 | ZRG1 |
| 2017 | Geostatistical software for space-time interpolation and uncertainty modeling2R44ES022113-02 | GOOVAERTS, PIERRE E | BIOMEDWARE, MI | $428,720 | ZRG1 |
| 2017 | Autonomous system supporting patient-specific transfer and discharge decisions1R43NR015945-01A1 | DAS, RITANKAR | DASCENA, INC., CA | $347,772 | ZRG1 |
| 2017 | A novel 3D-ultrasound platform using traditional 2D probes1R43NS097208-01A1 | HAYES, THOMAS JAMES | URSUS MEDICAL, LLC, PA | $341,520 | ZRG1 |
| 2017 | Antithrombotic Therapy with No Bleeding Risk for PCI1R44HL135993-01 | CHEN, RIDONG | APT THERAPEUTICS, INC., IL | $300,437 | ZRG1 |
| 2017 | Feasibility Study of New Method of Diagnostic and Prediction of Painful CIPN1R43CA206796-01A1 | NEMENOV, MIKHAIL I. | LASMED, LLC, CA | $300,000 | ZRG1 |
| 2017 | Development and Validation of a Collaborative Web-Based Quantitative Imaging and Dosimetry System for Radiopharmaceutical Therapy1R43CA213782-01 | FREY, ERIC C.GHALY, MICHAEL | RADIOPHARMACEUTICAL IMAGING AND DOSIMETRY, LLC, MD | $300,000 | ZRG1 |
| 2017 | Selection of a device for intranasal administration of a mucosal vaccine for HSV-21R43AI129378-01 | YANG, KEJIAN | BIOMEDICAL RESEARCH MODELS, INC., MA | $300,000 | ZRG1 |
| 2017 | Discovery of inhibitors of Zika virus1R43AI129009-01 | COBURN, GLEN ANDREW | VENATORX PHARMACEUTICALS, INC., PA | $299,999 | ZRG1 |
| 2017 | Screening for rAAV transduction enhancers1R43AI125043-01A1 | BOWLIN, TERRY L. | MICROBIOTIX, INC, MA | $299,999 | ZRG1 |
| 2017 | Targeting the checkpoint regulator VISTA for treatment of inflammatory disease1R44AI129182-01 | ROTHSTEIN, JAY L | IMMUNEXT, INC., NH | $299,938 | ZRG1 |
| 2017 | Enhancing cytarabine efficacy in leukemia through CDK8/19 inhibition1R43CA213629-01 | PORTER, DONALD C. | SENEX BIOTECHNOLOGY, INC., SC | $299,891 | ZRG1 |
| 2017 | A Rapid Paper Strip Nucleic Acid Test for the Point of Care Detection of Zika virus1R43AI129077-01 | CHO, HYUNDAE | CROSSLIFE TECHNOLOGIES, INC., CA | $299,574 | ZRG1 |
| 2017 | Development of an oxygen delivery biotherapeutic for the preservation of myocardial function during pediatric cardiopulmonary bypass1R44HD094414-01 | FINEMAN, JEFFREY RKRTOLICA, ANAMALTEPE, EMIN | OMNIOX, INC., CA | $298,396 | ZRG1 |
| 2017 | Aerosolized platinum nanoparticle chemotherapy for lung cancer1R43CA203142-01A1 | GROER, CHAD E. | NANOPHARM, LLC, KS | $298,065 | ZRG1 |
| 2017 | A Cytomegalovirus-based therapeutic vaccine for chronic hepatitis B1R44AI129232-01 | BRUENING, ERIC | TOMEGAVAX, INC., OR | $297,434 | ZRG1 |
| 2017 | Aminospectinomycin antibacterials for the treatment of antibiotic-resistant gonorrhea and other bacterial STDs1R43AI129008-01 | BUTLER, MICHELLE M. | MICROBIOTIX, INC, MA | $296,845 | ZRG1 |
| 2017 | Novel Therapeutics for Endothelial Dysfunction1R43TR001867-01 | HSU, SHEAU-YU TEDDY | ADEPTHERA, LLC, CA | $290,425 | ZRG1 |
| 2017 | Evaluate Efficacy of a JNK Lead Compound, IGP001, in an In Vivo Alzheimer’s Disease Model1R43AG054090-01A1 | CHEN, KAREN SANG | IMAGO PHARMACEUTICALS, INC., WY | $282,424 | ZRG1 |
| 2017 | Novel multifunctional oligosaccharide for treating sepsis and severe sepsis.1R43AI129164-01 | ACHARYA, SUCHISMITA | AYUVIS RESEARCH, INC., TX | $273,826 | ZRG1 |
| 2017 | Disaggregation of Toxic Protein Oligomers in Brain with Electromagnetic Treatment1R43NS090653-01A1 | ARENDASH, GARY W | NEUROEM THERAPEUTICS, INC., AZ | $255,391 | ZRG1 |
| 2017 | Direct sequencing of serum antibodies after infection1R43AI129082-01 | GUTHALS, ADRIAN | MAPP BIOPHARMACEUTICAL, INC., CA | $255,046 | ZRG1 |
| 2017 | Serotype independent therapeutic vaccine for Streptococcus pneumoniae1R43AI129218-01 | AMAN, M JAVAD | INTEGRATED BIOTHERAPEUTICS, INC., MD | $247,510 | ZRG1 |
| 2017 | Wearable technology to reduce risk of DVT and increase patient compliance1R43HL132624-01A1 | SCHWEGMAN, JEFFREY | RECOVERY FORCE, LLC, IN | $244,167 | ZRG1 |
| 2017 | Discriminating viral and bacterial meningitis infections with iDDS probes1R43AI129078-01 | SHAFER, DAVID A | GENETAG TECHNOLOGY, INC., GA | $242,611 | ZRG1 |
| 2017 | Development of a Homogeneous Screening Assay for the Tissue-Protective EPOR1R43TR001596-01A1 | MILLER, JAMES L | STATEGICS, INC., CA | $242,013 | ZRG1 |
| 2017 | Estimating disease risk using genetic data1R43HG009089-01A1 | FURLOTTE, NICHOLAS A. | 23ANDME, INC., CA | $241,905 | ZRG1 |
| 2017 | A novel biomaterial-based therapy utilizing auto-antigen and adjuvant for the amelioration of Type 1 Diabetes1R43AI129034-01 | MARSHALL, GREGORY PAUL | ONEVAX, LLC, FL | $238,328 | ZRG1 |
| 2017 | A mucosally targeted MERS-CoV vaccine produced in plants1R43AI122551-01A1 | WYCOFF, KEITH | PLANET BIOTECHNOLOGY, INC., CA | $236,488 | ZRG1 |
| 2017 | "Modulation of Immune Checkpoints by Self-Deliverable RNAi for Adoptive Cell Transfer"1R43CA213632-01 | WOLFSON, ALEXEY | ADVANCED RNA TECHNOLOGIES, LLC, CO | $231,500 | ZRG1 |
| 2017 | Assembled Porous Silica Membranes for Biomolecule SPE1R43GM122098-01 | BOYES, BARRY E | ADVANCED MATERIALS TECHNOLOGY, INC., DE | $231,421 | ZRG1 |
| 2017 | A Topical Nrf2 Activator for Oral Mucositis1R43DE026086-01A1 | HYBERTSON, BROOKS MICHAEL | PATHWAYS BIOSCIENCE, LLC, CO | $229,248 | ZRG1 |
| 2017 | A Yeast based Immunotherapy against Clostridium difficile Infection1R43AI129044-01 | YANG, ZHIYONG | FZATA, INC., MD | $225,068 | ZRG1 |
| 2017 | FMRI Dynamic Phantom for Improved Detection of Resting-State Brain Networks1R44DA043277-01 | KRIEGSTEIN, ALANMUJICA-PARODI, LILIANNE R | ALA SCIENTIFIC INSTRUMENTS, INC., NY | $225,028 | ZRG1 |
| 2017 | An interactive, patient-specific virtual surgical planning system for upper airway obstruction treatments1R43EB023121-01 | ENQUOBAHRIE, ANDINET ASMAMAW | KITWARE, INC., NY | $225,000 | ZRG1 |
| 2017 | Novel AMPK Activators for the Treatment of Neuropathic Pain1R43GM119596-01A1 | DAX, SCOTT L | CERSCI THERAPEUTICS, INC., TX | $225,000 | ZRG1 |
| 2017 | An interactive App to Promote Safe and Effective use of Opioids in Young Children Postoperatively1R43DA042645-01 | LEVINE, ROBERT J | ARCHIEMD, INC., FL | $225,000 | ZRG1 |
| 2017 | Evaluation of Natural Products and Derivatives as Antimalarial Agents1R43AI128888-01 | ZHU, SHUREN | CASCADE THERAPEUTICS, INC., MD | $225,000 | ZRG1 |
| 2017 | A Novel, Non-Cytotoxic, Epigenetic Therapeutic for Sickle Cell Disease1R44HL135896-01 | DESIMONE, JOSEPHSAUNTHARARAJAH, YOGEN | DENOVOTHERAPIES, LLC, OH | $225,000 | ZRG1 |
| 2017 | Media-based youth e-cig prevention toolkit for community-based organizations1R44DA041004-01A1 | HOLTZ, KRISTEN D | KDH RESEARCH AND COMMUNICATION, INC., GA | $225,000 | ZRG1 |
| 2017 | Genome Mining the Full Diversity of the Actinomycete Biosynthetic Universe for Neomorph Antibiotic Discovery1R43AI129043-01 | GRAY, DANIELPHAN, LY | WARP DRIVE BIO, INC, MA | $225,000 | ZRG1 |
| 2017 | Practical Mass Spectrometry Upgrade for Identifying Fragile Protein Modifications by ECD1R43GM122131-01 | VOINOV, VALERY G. | E-MSION, INC., OR | $225,000 | ZRG1 |
| 2017 | Biosynthesis of novel and natural plant alkaloid compounds for drug production and discovery1R43AT009419-01 | HAWKINS, KRISTY | ANTHEIA, INC., CA | $225,000 | ZRG1 |
| 2017 | ENaC inhibiting peptide for Cystic Fibrosis delivered by Dry Powder Inhaler1R43HL135951-01 | CROWDER, TIMOTHY | SPYRYX BIOSCIENCES, INC., NC | $225,000 | ZRG1 |
| 2017 | NeuroGoggle: A Portable Brain-based Device for Assessing Visual Function Deficits1R43EY027651-01 | ZAO, JOHN KAR-KIN | NGOGGLE, INC., CA | $225,000 | ZRG1 |
| 2017 | A Rapid, Low-Cost Point of Care Diagnostic for detection of Zika virus RNA1R43AI129126-01 | USMANI-BROWN, SAHAR | L2 DIAGNOSTICS, LLC, CT | $225,000 | ZRG1 |
| 2017 | Advances in contact lens materials to extend wear time for a new standard in vision correction and future medical devices1R43EY027239-01A1 | DOMSZY, ROMAN | INDUSTRIAL SCIENCE & TECHNOLOGY NETWORK, PA | $225,000 | ZRG1 |
| 2017 | Plastic Parenteral Container with Superior Barrier Properties for Biologics1R43HL129622-01A1 | JONSEN, DANIEL EVERETT | TRIBOFILM RESEARCH, INC., NC | $224,993 | ZRG1 |
| 2017 | Mindfulness Mobile App to Reduce Adolescent Substance Use1R43DA043288-01 | SMITH, DANA K | OREGON RES BEHAVIORAL INTERVENTION STRAT, OR | $224,985 | ZRG1 |
| 2017 | Novel xenogeneic extracellular matrix biomaterial for cardiovascular prostheses1R43HL136003-01 | WONG, MAELENE L | VIVITA TECHNOLOGIES, INC., CA | $224,976 | ZRG1 |
| 2017 | Preclinical Evaluation of Ancestral Coagulation Factor VIII1R43HL135969-01 | DENNING, GABRIELADOERING, CHRISTOPHER BRADLEYSPENCER, H TRENT | EXPRESSION THERAPEUTICS, GA | $224,976 | ZRG1 |
| 2017 | Promoting AdheRence via Objective Technology to Assess Cystic Fibrosis Treatment (PROTRACT)1R43HL132650-01A1 | KREPKOVICH, EILEEN T. | BARRON ASSOCIATES, INC., VA | $224,966 | ZRG1 |
| 2017 | Rapid and Low- cost POC Assay for Zika Virus Diagnosis1R43AI129061-01 | WONG, SEASON S-S | AI BIOSCIENCES, INC., TX | $224,955 | ZRG1 |
| 2017 | Wireless System for Ambulatory Rodents to Measure Pressure and Volume in the Left Ventricle1R43HL132705-01A1 | RIEHLE, TIMOTHY H. | KORONIS BIOMEDICAL TECHNOLOGIES CORPORAT, MN | $224,953 | ZRG1 |
| 2017 | Digital serology for parallel parasitic disease detection1R43AI129113-01 | DAUGHERTY, PATRICK S | SERIMMUNE, INC., CA | $224,950 | ZRG1 |
| 2017 | Continuous Data Collection and Analysis for Stroke Prevention using a Wearable Sensor1R43AG058516-01 | LICHTER, PATRICK | KORONIS BIOMEDICAL TECHNOLOGIES CORPORAT, MN | $224,942 | ZRG1 |
| 2017 | High-throughput screening of arrayed single cells for automated analysis of phenotypic heterogeneity1R43GM122149-01 | FORBES, ZACHARY GRAHAM | CELLDOM, INC., CA | $224,907 | ZRG1 |
| 2017 | Novel enzyme inhibitor screening platform using modified designer nucleosomes1R43GM119893-01A1 | SUN, ZU-WEN | EPICYPHER, INC., NC | $224,881 | ZRG1 |
| 2017 | Comprehensive Eye Evaluation Algorithm: CEEvA1R43EY026832-01A1 | BAUMAN, WENDALL CMANIVANNAN, NIRANCHANAZAMORA, GILBERTO | VISIONQUEST BIOMEDICAL, LLC, NM | $224,791 | ZRG1 |
| 2017 | GC4419, an SOD Mimetic, as a Radiomodulator in Lung Cancer Patients Treated with SBRT1R44CA206795-01A1 | KEENE, JEFFERY LYNNSTORY, MICHAEL DEAN | GALERA THERAPEUTICS, LLC, PA | $224,736 | ZRG1 |
| 2017 | Establishment of a patient-like mouse models of soft-tissue sarcoma sub-types1R43CA213649-01 | HOFFMAN, ROBERT M | ANTICANCER, INC., CA | $224,700 | ZRG1 |
| 2017 | New Endothelial Cell-Based Assay to Assess Variability of Nitric Oxide Production in Humans1R43ES027716-01 | KINEV, ALEXANDER | CREATIVE SCIENTIST, INC., NC | $224,460 | ZRG1 |
| 2017 | Commercial Software Using High-throughput Computational Techniques to Improve Genome Analysis1R44HG009474-01 | KIEL, MARK JULIN | GENOMENON, INC., MI | $224,417 | ZRG1 |
| 2017 | Sensitive and Portable Physician Office-Based Urine Analyzer to Tackle Prescription Drug Abuse1R43DA043325-01 | HEFFERNAN, MICHAEL JOHN | BREVITEST TECHNOLOGIES, INC., TX | $224,415 | ZRG1 |
| 2017 | Degradable hydrogel for retinal tamponade1R43EY027635-01 | BRAITHWAITE, GAVIN JAMES | CAMBRIDGE POLYMER GROUP, INC., MA | $224,397 | ZRG1 |
| 2017 | Sustained 3-Month Delivery of Olanzapine for Schizophrenia Maintenance Treatment1R43MH112240-01 | MARTIN, FRANCIS JOSEPH | DELPOR, INC., CA | $224,389 | ZRG1 |
| 2017 | Minimally Invasive Cardiac Sympathetic Denervation for Malignant Ventricular Arrhythmia1R44HL135957-01 | LEVIN, HOWARD D | CORIDEA, LLC, NY | $224,221 | ZRG1 |
| 2017 | Direct Conversion of Human Fibroblasts into Neuronal Cells by Small Molecules (hCiN)1R43DA041997-01A1 | ESMAELI-AZAD, BABAK | CIBOTS, INC., CA | $223,988 | ZRG1 |
| 2017 | Surgical Wound Closure Matrices for the Prevention of Superficial Incisional SSI1R43GM122226-01 | MEHTA, MANAV | GEL4MED, INC., MA | $223,866 | ZRG1 |
| 2017 | Development of multispecific antibodies for the treatment of Pseudomonas aeruginosa infection1R44AI129161-01 | HOLLANDS, ANDREW STEPHEN | INHIBRX, INC., CA | $223,854 | ZRG1 |
| 2017 | Retinal image analysis software for neurodegenerative disease research1R43TR001890-01 | RUSSAKOFF, DANIEL | VOXELERON, LLC, CA | $222,991 | ZRG1 |
| 2017 | Optical Dosimeter-guided Photodynamic Therapy1R43CA213607-01 | DAVIS, STEVEN J | PHYSICAL SCIENCES, INC, MA | $222,555 | ZRG1 |
| 2017 | A High School Program for Preventing Prescription Drug Abuse1R44DA043273-01 | GRIFFIN, KENNETH W | NATIONAL HEALTH PROMOTION ASSOCIATES, NY | $220,878 | ZRG1 |
| 2017 | The Oaks: A Mobile Exercise and Education Program for People with Osteoarthritis of the Knee1R44AG055341-01 | FLYNN, SHERYL | BLUE MARBLE REHAB, INC., CA | $220,137 | ZRG1 |
| 2017 | Optogenetic control over transgene expression for the therapy of brain and spine1R43MH110273-01A1 | MYAKISHEV-REMPEL, MAX | LOCALIZED THERAPEUTICS, LLC, CA | $220,083 | ZRG1 |
| 2017 | Microfluidic S-nitrosothiol Sensor1R43GM122152-01 | MCDUNN, JONATHAN EDWARD | CLINICAL SENSORS, INC., NC | $215,501 | ZRG1 |
| 2017 | Subcutaneous Replacement Enzymes for Fabry Disease1R43TR001884-01 | CAO, MINGJU | KINETIQ, INC., CA | $211,668 | ZRG1 |
| 2017 | Supporting Healthy Aging with a Phytochemical Combination that Acts at Multiple Control Points in the Nrf2 Activation Pathway1R43AG053128-01A1 | HYBERTSON, BROOKS MICHAEL | PATHWAYS BIOSCIENCE, LLC, CO | $209,928 | ZRG1 |
| 2017 | Cost effective high-quality genome assembly for non-model organisms1R43HG009482-01 | TAYLOR, RYAN WALDO | END2END GENOMICS, LLC, CA | $204,240 | ZRG1 |
| 2017 | Fully modified bispecific aptamer for effective wet AMD combination treatment1R43EY027634-01 | GONG, QIANG | APTITUDE MEDICAL SYSTEMS, INC., CA | $202,821 | ZRG1 |
| 2017 | Targeting the alternative pathway to treat age-related macular degeneration1R43EY026860-01A1 | SCHRAMM, ELIZABETH | SERION, INC., MO | $198,151 | ZRG1 |
| 2017 | Fluorescent reporters for real-time single-cell Pol III transcription measurement1R43GM122166-01 | WU, KAREN | LUCERNA, INC., NY | $176,165 | ZRG1 |
| 2017 | Increasing available choices for conjugate vaccine technology by producing carrier proteins in Scarab Genomics’ reduced genome E. coli strains1R44AI129149-01 | BLATTNER, FREDERICK RLANDRY, CHARLES F | SCARAB GENOMICS, LLC, WI | $154,222 | ZRG1 |
| 2017 | Enhancing CRISPR-based Therapeutic Interventions Via a Targeted Platform Tool1R43TR001897-01 | LAPPI, DOUGLAS A | ADVANCED TARGETING SYSTEMS, INC., CA | $150,000 | ZRG1 |
| 2017 | A Metabologenomics Platform for Large-Scale, High-Throughput Natural Product Discovery1R43AT009417-01 | GOERING, ANTHONY WHITNEY | MICROBIAL PHARMACEUTICALS, INC., IL | $150,000 | ZRG1 |
| 2017 | Centralized assay datasets for modelling support of small drug discovery organizations1R43GM122196-01 | EKINS, SEAN | COLLABORATIONS PHARMACEUTICALS, INC., NC | $149,999 | ZRG1 |
| 2017 | Fixed site and wearable monitors for assessment of personal exposure to airborne chemicals1R43ES027736-01 | KADOSSOV, EVGUENI | XPLOSAFE, LLC, OK | $149,999 | ZRG1 |
| 2017 | Laboratory Bench-Top EXAFS with STJ Spectrometer1R43GM122163-01 | CARPENTER, MATTHEW H | STAR CRYOELECTRONICS, LLC, NM | $149,997 | ZRG1 |
| 2017 | iCardioTox Profiler - Developing a Novel In Vitro Assay to Assess Cardiotoxicity Using a Panel of Patient-derived Cardiomyocytes1R43HL135916-01 | KIM, KEVIN J | STEM CELL THERANOSTICS, INC, CA | $149,981 | ZRG1 |
| 2017 | Long non-coding RNA signatures to distinguish fibromyalgia syndrome from rheumatic diseases1R43AI129147-01 | AUNE, THOMAS M.SPURLOCK, CHARLES FLOYD | IQUITY LABS, INC, TN | $149,286 | ZRG1 |
| 2017 | Improved pulse oximetry performance using transmission optical flowmetry.1R43GM122132-01 | RICE, TYLER | LASER ASSOCIATED SCIENCES, INC., CA | $149,237 | ZRG1 |
| 2017 | Retinal birefringence imaging for pediatric vision screening1R43EY027633-01 | SHAKA, JUSTINWINSOR, ROBERT | REBISCAN, LLC, MA | $149,152 | ZRG1 |
| 2017 | A Phase I Clinical Trial: Binary Therapy with DM-CHOC-PEN and WBRT in Adults with Cancer Involving the CNS1R43CA213545-01 | MORGAN, LEE ROY | DEKK-TEC, INC., LA | $143,294 | ZRG1 |
| 2017 | A wearable tech app for Checkup&Choices1R43AA025502-01 | CAMPBELL, WILLIAM P | CHECKUP AND CHOICES, LLC, NM | $139,977 | ZRG1 |
| 2017 | High sensitive and specific, Point-of-use lateral flow strip for on-site test of cannabis intoxication1R43DA042664-01 | ZHOU, XICHUN | VITAN-BIOTECH, LLC, CO | $131,697 | ZRG1 |
| 2017 | Development of Multispecific Antibodies for the treatment of Methicillin Resistant Staphylococcus aureus (MRSA) infection1R43AI129162-01 | HOLLANDS, ANDREW STEPHEN | INHIBRX, INC., CA | $108,396 | ZRG1 |
| 2016 | Improved Oral P-selectin Blocker for Prophylactic Sickle Cell Disease Therapy2R44HL123059-02A1 | EMBURY, STEPHEN H. | VANGUARD THERAPEUTICS, INC., CA | $1,668,155 | ZRG1 |
| 2016 | Development of an ophthalmic diagnostic probe for neurodegenerativedisorders2R44AG050454-02 | SARRAF, STELLA | AMYDIS DIAGNOSTICS, INC., CA | $1,647,908 | ZRG1 |
| 2016 | Characterization of a low mutation rate E. coli in extended fermentation2R44GM105177-02 · under PA-14-071 | BLATTNER, FREDERICK RFRISCH, DAVID A | SCARAB GENOMICS, LLC, WI | $1,554,424 | ZRG1 |
| 2016 | Arenavirus Antiviral Lead Optimization2R44AI112097-03 · under PA-14-071 | HENKEL, GREGORY WILLIAMPLEWE, MICHAEL BRUNO | ARISAN THERAPEUTICS, INC., CA | $1,500,000 | ZRG1 |
| 2016 | Advanced morphological analysis of cerebral blood flow for acute concussion diagnosis and return-to-play determination2R44NS092209-02 | HAMILTON, ROBERT | NEURAL ANALYTICS, INC., CA | $1,500,000 | ZRG1 |
| 2016 | Novel drug VS-105 for treatment of osteoporosis2R44AR065247-02 · under PA-14-071 | WU-WONG, JINSHYUN RUTH | VIDASYM, INC., SD | $1,480,983 | ZRG1 |
| 2016 | Multi Source E-Beam kV X-Ray Tube for Image-Guided Radiotheraphy2R44CA192498-02 | BOYD, DOUGLAS P | TELESECURITY SCIENCES, INC., NV | $1,254,926 | ZRG1 |
| 2016 | A Proton Radiography System for Optimization of Proton Therapy2R44CA203499-02 | DEJONGH, DON F | PROTONVDA LLC, IL | $1,248,811 | ZRG1 |
| 2016 | Restoration of free radical homeostasis: novel therapy of septic shock2R44GM100503-02A1 | SALZMAN, ANDREW LURIE | RADIKAL THERAPEUTICS, INC., MA | $1,248,631 | ZRG1 |
| 2016 | Integrated System for FFPE Sample Preparation2R44CA186384-02A1 | KELLOGG, GREGORY JOHN | COVARIS, INC., MA | $1,227,038 | ZRG1 |
| 2016 | Validation of a human in vitro system of hepatic steatohepatitis2R44DK100136-02A1 | WAMHOFF, BRIAN ROBERT | HEMOSHEAR THERAPEUTICS, LLC, VA | $1,210,475 | ZRG1 |
| 2016 | Development and Validation of the Miya Model, A Simulator Designed to Train Vaginal Surgery Techniques2R44HD084151-02 | CHEN, CHI CHIUNG GRACEDESTEPHANO, CHRISTOPHERKAMMIRE, LESLIELOCKROW, ERNESTMATTHEWS, CATHERINE ANNMIYAZAKI, DOUGLAS W.NIHIRA, MIKIO | MIYAZAKI ENTERPRISES, LLC, NC | $1,169,878 | ZRG1 |
| 2016 | Shape Memory Polymer Vascular Occlusion Device for the Treatment of Venous Insufficiency Phase II2R44EB022016-02A1 | LANDSMAN, TODD | SHAPE MEMORY MEDICAL INC., CA | $1,162,700 | ZRG1 |
| 2016 | A Vaccine for Schistosomiasis, "SchistoShield"2R44AI103983-03A1 · under PA-14-071 | CARTER, DARRICK ALBERTSIDDIQUI, AFZAL A | PAI LIFE SCIENCES, INC., WA | $1,159,786 | ZRG1 |
| 2016 | Reducing Brain Injury After Focal Ischemia Using a Nitric Oxide-Neutral Oxygen Carrier2R44NS076272-02A1 | CARY, STEPHENLE MOAN, NATACHA | OMNIOX, INC., CA | $1,115,299 | ZRG1 |
| 2016 | Improving red blood cell transfusion through systems biology2R44HL123074-02 · under PA-14-071 | BORDBAR, AARASH | SINOPIA BIOSCIENCES, INC., CA | $1,029,290 | ZRG1 |
| 2016 | Video Rate optical verification tool for radiotherapy treatment plans2R44CA199681-02 | WARE, WILLIAM | DOSEOPTICS, LLC, NH | $1,016,414 | ZRG1 |
| 2016 | Modulated Imaging in Comprehensive Assessment of Diabetic Foot Ulcer Development and Healing2R44DK094625-02A1 | CUCCIA, DAVID JMAZHAR, AMAAN | MODULATED IMAGING, INC., CA | $1,015,160 | ZRG1 |
| 2016 | CorBand: A novel wearable wrist sensor for heart failure remote monitoring2R44HL125001-02 | NAIMA, REZA | RETHINK MEDICAL, INC., CA | $1,009,410 | ZRG1 |
| 2016 | Development and Commercialization of an Innovative Rapid HIV-1 Incidence Assay2R44AI114365-02A1 | MINK, RONALD WILLIAM | SEDIA BIOSCIENCES CORPORATION, OR | $1,000,000 | ZRG1 |
| 2016 | Plant-derived HIV neutralizing mAbs for passive immunotherapy in newborn macaques2R44AI081621-04A1 | ROSENBERG, YVONNE J | PLANTVAX, INC., MD | $1,000,000 | ZRG1 |
| 2016 | TP508: A New Drug for Mitigating Lethals Effects of Radiation Exposure2R44AI086135-05 | CARNEY, DARRELL H.SOWER, LAURIE E | CHRYSALIS BIOTHERAPEUTICS, INC., TX | $1,000,000 | ZRG1 |
| 2016 | Optimization of a clinical stage nanoparticle drug delivery platform2R44CA186410-02A1 | BROWN, BOB D. | DICERNA PHARMACEUTICALS, INC., MA | $1,000,000 | ZRG1 |
| 2016 | Customized Nanotechnology Based Treatment of Oral Cancer2R44DE023725-02 · under PA-14-071 | GOLDBERG, MANIJEH N | PRIVO TECHNOLOGIES, LLC, MA | $999,997 | ZRG1 |
| 2016 | Therapeutic Antibodies for Biofilm Infections2R44AI120425-02 | KAUVAR, LAWRENCE MICHAEL | TRELLIS BIOSCIENCE, INC., CA | $999,628 | ZRG1 |
| 2016 | Preventing and treating RSV pneumonia in immunocompromised cancer patients2R44HL118926-02 · under PA-14-071 | SCOTT, BRENTON | PULMOTECT, INC, TX | $999,372 | ZRG1 |
| 2016 | Innovative Optical System for Hemagglutination Assays2R44AI106054-03A1 | ROWLEN, KATHY L | INDEVR, INC., CO | $996,634 | ZRG1 |
| 2016 | Preclinical development of a potent D-peptide RSV inhibitor2R44AI098197-03A1 | WELCH, BRETT D | NAVIGEN, INC., UT | $992,263 | ZRG1 |
| 2016 | Overcoming Tramadol Resistance In CYP2D6 Poor Metabolizers: A Phase 1 Trial Demonstrating Analgesic Superiority of Omnitram to Tramadol in Subjects Coadministered Paroxetine2R44DA027304-05 | KAHN, STUART JZEBALA, JOHN A | SYNTRIX BIOSYSTEMS, INC., WA | $990,418 | ZRG1 |
| 2016 | A method for preparing unbiased miRNA sequencing libraries (miR-ACS)2R44HG007788-02A1 | KAZAKOV, SERGEI A | SOMAGENICS, INC., CA | $990,251 | ZRG1 |
| 2016 | Universal Attenuated Sporozoite Vaccine and Challenge System2R44AI058375-09 | HOFFMAN, STEPHEN LEV | SANARIA, INC., MD | $989,298 | ZRG1 |
| 2016 | Advanced Image Analysis Tools for Diabetic Retinopathy Telemedicine Application2R44EY026864-05 | SOLANKI, KAUSHAL | EYENUK, INC., CA | $984,026 | ZRG1 |
| 2016 | Radiation Sterilizable Small Size RFID Tags for Biomedical Samples2R44OD020162-02 | DAVIDOWITZ, HANANEL | BIO TILLION, LLC, NJ | $961,641 | ZRG1 |
| 2016 | SAMBA HIV-1 Semi-quantitative whole blood test for resource limited settings2R44AI097120-05 | LEE, HELEN H | DIAGNOSTICS FOR THE REAL WORLD, LTD, CA | $951,508 | ZRG1 |
| 2016 | A Cytomegalovirus-based therapeutic vaccine against oncogenic human papillomaviruses2R44CA180177-02 | BRUENING, ERIC | TOMEGAVAX, INC., OR | $948,184 | ZRG1 |
| 2016 | Compact super-directional microphone array to improve hearing in background noise2R44DC014169-02 | ELKO, GARY W. | MH ACOUSTICS, LLC, NJ | $945,095 | ZRG1 |
| 2016 | Validation and qualification of an ex vivo human cardiac tissue-based assay for the assessment of the potential cardiotoxicity of pharmaceutical compounds2R44TR001133-02A1 | GHETTI, ANDREA | ANABIOS CORPORATION, CA | $945,014 | ZRG1 |
| 2016 | Safe and effective anti CD154 antibodies for therapeutic intervention2R44AI098261-05 | ROTHSTEIN, JAY L | IMMUNEXT, INC., NH | $912,191 | ZRG1 |
| 2016 | Development of Monoclonal Antibodies to Treat Pancreatic Cancer2R44CA174025-02 | SUREBAN, SRIPATHI M | COARE BIOTECHNOLOGY, INC., OK | $905,989 | ZRG1 |
| 2016 | Activate Silent and Cryptic Intact Fungal SM Gene Clusters through FACs for Novel Antibiotics Discovery2R44AI118086-02 | BOK, JIN WOOKELLEHER, NEIL LWU, CHENGCANG CHARLES | INTACT GENOMICS, INC., MO | $900,553 | ZRG1 |
| 2016 | Low Insertion Force Epidural, Actuated Needle System for Enhanced Control and Tactile Feel During Epidural Insertion2R44GM085844-04A1 · under PA-14-071 | MULVIHILL, MAUREEN L. | ACTUATED MEDICAL, INC., PA | $898,850 | ZRG1 |
| 2016 | Novel Nanofiltration Membranes for Isolation of Pharmaceutical Compounds II2R44GM103402-03 | PENNISI, KENNETH J | COMPACT MEMBRANE SYSTEMS, INC., DE | $896,762 | ZRG1 |
| 2016 | High Speed Multiphoton Multifocal Whole Brain Imaging2R44NS087767-02 | RAGAN, TIMOTHY M. | TISSUEVISION, INC., MA | $885,211 | ZRG1 |
| 2016 | Kinome-wide Cell-Based Assays2R44GM109740-02 · under PA-14-071 | ZUTSHI, REENA | LUCEOME BIOTECHNOLOGIES, LLC, AZ | $873,704 | ZRG1 |
| 2016 | Interactive Technology for Hearing Aid Education and Acceptance2R44AG045947-02A1 | LETZT, ALAN | HEALTHCARE TECHNOLOGIES AND METHODS, VA | $861,278 | ZRG1 |
| 2016 | Therapeutic Reversal of Endothelial Dysfunction in Atherogenesis2R44HL118826-03A1 | ADAMS, WILLIAM JAMESGARCIA-CARDENA, GUILLERMO | RIPARIAN PHARMACEUTICALS, INC., MA | $857,294 | ZRG1 |
| 2016 | Development of SUPR peptides as PET Imaging Agents for Her2+ Breast Cancer2R44CA206771-02 | FIACCO, STEPHENMILLWARD, STEVEN W | EVORX TECHNOLOGIES, INC., CA | $855,568 | ZRG1 |
| 2016 | Development of the RXR agonist IRX4204 to treat Multiple Sclerosis and other Immune related Diseases2R44AI112512-02A1 | CHANDRARATNA, ROSH | IO THERAPEUTICS, INC., CA | $854,395 | ZRG1 |
| 2016 | Intervening to Prevent Youth Access to Marijuana Phase II2R44DA038933-02 | BULLER, DAVID B | KLEIN BUENDEL, INC., CO | $848,974 | ZRG1 |
| 2016 | Refinement of an Autocidal Gravid Ovitrap for mass-manufacturing2R44AI115782-02 | BANFIELD, MICHAEL GILBERTBESS, EMILIE | BANFIELDBIO INC., WA | $848,707 | ZRG1 |
| 2016 | One Step, POC Sample to Answer Process for RNA Analysis Outside the Laboratory2R44GM106496-02 | MUELLER, JOHN E | LYNNTECH, INC., TX | $833,462 | ZRG1 |
| 2016 | Ocular Flare Meter (OFAM) Development Phase II2R44EY022548-02A1 | MENON, NARESH | CHROMOLOGIC, LLC, CA | $830,773 | ZRG1 |
| 2016 | High throughput laboratory X-ray illumination system for protein crystallography and screening2R44GM112287-02 | YUN, WENBING | SIGRAY, INC., CA | $825,315 | ZRG1 |
| 2016 | Malarial Retinopathy Screening System for Improved Diagnosis of Cerebral Malaria2R44AI112164-03A1 | HARDING, SIMONJOSHI, VINAYAK SLEWALLEN, SUSAN | VISIONQUEST BIOMEDICAL, LLC, NM | $821,709 | ZRG1 |
| 2016 | Development of a treatment for voiding dysfunction in spinal cord injured patients2R44HD080263-02A1 | MARSON, LESLEY | DIGNIFY THERAPEUTICS, LLC, NC | $818,347 | ZRG1 |
| 2016 | Novel DNA-Launched Attenuated Vaccine for VEE Virus SBIR Phase II2R44AI094863-03A1 · under PA-14-071 | PUSHKO, PETER M. | MEDIGEN, INC., MD | $811,565 | ZRG1 |
| 2016 | Novel Therapeutic Approach to Hypercholesterolemia Using Anti-PCSK9 Selected Immune Repertoires2R44HL121909-02 · under PA-14-071 | SHIMKETS, RICHARD AUGUST | ABEOME CORPORATION, GA | $809,592 | ZRG1 |
| 2016 | Portable Transdermal Acoustic Patch for Delivery of Large Molecules to Improve HIV Patient Medication Regime Compliance by Elimination of Side-Effects, Including Injection Site Reactions2R44AI080335-04 | MULVIHILL, MAUREEN L. | ACTUATED MEDICAL, INC., PA | $808,204 | ZRG1 |
| 2016 | Safety Studies for Clinical Trials of a Botanical Drug for Sickle Cell Disease2R44HL119086-02 · under PA-14-071 | SWIFT, ROBERT | INVENUX, LLC, CO | $807,410 | ZRG1 |
| 2016 | SELF-NEUTRALIZING OLIGONUCLEOTIDES WITH ENHANCED CELLULAR UPTAKE2R44GM109517-02 | TABATADZE, DAVID R | ZATA PHARMACEUTICALS, INC., MA | $796,420 | ZRG1 |
| 2016 | Novel Debridement for Necrotic Tissue2R44GM113284-02A1 | LEUNG, KELLY XSALAMONE, JOSEPH C. | ROCHAL INDUSTRIES, LLC, TX | $789,877 | ZRG1 |
| 2016 | A New Technique for Diabetic Foot Ulcers2R44DK105692-02 | CHIEN, SUFAN | NOVERATECH, LLC, KY | $781,613 | ZRG1 |
| 2016 | Development and validation of a human brown adipocyte system2R44DK103479-02 | LEA-CURRIE, YOLANDA RENEEVAN KANEGAN, MICHAEL JOSEPH | ZEN-BIO, INC., NC | $777,915 | ZRG1 |
| 2016 | Microfabricated Cochlear Electrode Array2R44DC012741-02 | JOHNSON, ANGELIQUE | MEMSTIM, LLC, KY | $767,241 | ZRG1 |
| 2016 | Improving Clinical Encounter Communications to Enhance Minority Diabetes Care2R44MD009559-02 | ZACHARY, WAYNE W | STARSHIP HEALTH TECHNOLOGIES, PA | $766,020 | ZRG1 |
| 2016 | Nanowire Sensor Array-based Assay for Early Diagnosis of Alzheimer's Disease2R44AG046059-02A1 | ALAM, MAKSUDUL | INNOSENSE, LLC, CA | $764,989 | ZRG1 |
| 2016 | Child Safety Seat with Advanced Harness System2R44HD083878-02 | SEIFERT, SARA | MINNESOTA HEALTHSOLUTIONS CORPORATION, MN | $764,633 | ZRG1 |
| 2016 | The VesiVax® System: Vaccine Development Made Easy2R44AI094770-03A1 | HO, SAMON | MOLECULAR EXPRESS, INC., CA | $762,253 | ZRG1 |
| 2016 | Ultra-sensitive method for HIV p24 antigen detection2R44AI083169-04A1 | BYSTRYAK, SIMON | ALLIED INNOVATIVE SYSTEMS, LLC, NJ | $761,372 | ZRG1 |
| 2016 | A high throughput, high resolution, and high sensitivity scanning X-ray fluorescence microprobe for elemental mapping in cell cultures and tissues for medical research and diagnosis2R44GM112413-02 · under PA-14-071 | YUN, WENBING | SIGRAY, INC., CA | $759,237 | ZRG1 |
| 2016 | Mass Spectrometric Bead-Imaging of Off-Target Drug Interactions2R44GM105249-03 | LIM, MARK | AMBERGEN, INC, MA | $753,500 | ZRG1 |
Showing the 200 most recent of 2,074 awards.
Data: Grants.gov's daily extract and NIH's notice pages and award files, in ScienceGraph release conductgrants-2026-11-09-0.1.0. An award is listed only where NIH's own record names the notice, and a PI only by NIH's profile ID. Grants.gov and NIH do not endorse ScienceDex.